PC
ZNTL icon

Polar Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Polar Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$8.83M Buy
+270,000
New +$9.45M 0.07% 186

Other funds holding ZNTL

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Polar Capital's ZNTL Position: Q3 2020 in Review

Polar Capital opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2020: 270,000 shares worth $8.83M. The stake represents 0.07% of the portfolio and ranks #186 among its holdings.

66 funds tracked by Wall St. Rank hold ZNTL as of Q3 2020.

  • Polar Capital held 270,000 shares of Zentalis Pharmaceuticals worth $8.83M as of Q3 2020.
  • Zentalis Pharmaceuticals was a new Polar Capital position in Q3 2020.
  • Zentalis Pharmaceuticals made up 0.07% of Polar Capital's portfolio in Q3 2020, its #186 holding.
  • 66 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.